ESC 2022: Results from the AXIOMATIC-SSP Trial: | Dr Mukul Sharma

Подробнее о видео

Watch on Radcliffe Cardiology: *1wlxich*_ga*MTE1NzYxMzg0NC4xNjYxNTg2ODk0*_ga_T874FCJ3LG*MTY2MTY4NzY0My4xNC4xLjE2NjE2ODc3MzkuMC4wLjA.&utm_source=youtube&utm_medium=organic_social&utm_term=&utm_campaign=DELV-6605&utm_content=esc_sharma

We are joined onsite by Dr Mukul Sharma (Mcmaster University, CA) to discuss the findings of the AXIOMATIC-SSP (NCT03766581) trial.

This study aimed to evaluate the effectiveness of oral Factor XIa inhibitor milvexian in addition to aspirin and clopidogrel as compared to standard therapies in secondary stroke prevention. 2366 participants were involved in the trial, and were randomized between differing specified doses of the drugs, or a placebo.

Questions:
-What is the rationale behind using Milvexian in addition to DOACs in patients with ischemic stroke?
-What was the study design and key outcomes?
-What are the next steps for Phase III Trials for the use of milvexian?
-If this use of milvexian is implemented in clinical practice, what could be the impact on both clinicians and patients?

This content is intended for healthcare professionals only.

Radcliffe brings medical knowledge, insight and innovation to life for CV clinicians around the world, using our communications & creative expertise, our platforms and connections across the community to help transform theory into practice faster.